Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Long-Term Debt Repayments (2021 - 2024)

Serina Therapeutics (SER) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $1000.0 as the latest value for Q4 2024.

  • Quarterly Long-Term Debt Repayments fell 92.31% to $1000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Sep 2025, down 97.87% year-over-year, with the annual reading at $35000.0 for FY2024, 27.08% down from the prior year.
  • Long-Term Debt Repayments hit $1000.0 in Q4 2024 for Serina Therapeutics, down from $8000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $250000.0 in Q1 2021 to a low of $1000.0 in Q4 2024.
  • Historically, Long-Term Debt Repayments has averaged $37000.0 across 3 years, with a median of $12000.0 in 2023.
  • Biggest YoY gain for Long-Term Debt Repayments was 18.18% in 2024; the steepest drop was 92.31% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $250000.0 in 2021, then crashed by 94.8% to $13000.0 in 2023, then plummeted by 92.31% to $1000.0 in 2024.
  • Business Quant data shows Long-Term Debt Repayments for SER at $1000.0 in Q4 2024, $8000.0 in Q3 2024, and $13000.0 in Q2 2024.